アレルギー診断薬と治療薬の市場規模、シェア、動向分析レポート:タイプ別(診断薬、治療薬)、アレルゲンタイプ別(食品、吸入、薬剤)、検査タイプ別、地域別、セグメント別予測、2024年~2030年Allergy Diagnostics And Therapeutics Market Size, Share & Trends Analysis Report By Type (Diagnostics, Therapeutics), By Allergen Type (Food, Inhaled, Drug), By Test Type, By Region, And Segment Forecasts, 2024 - 2030 アレルギー診断と治療薬市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界のアレルギー診断・治療薬市場規模は2023年に583億1000万米ドルと推定され、2024年から2030年にかけて年平均... もっと見る
1~3営業日
サマリーアレルギー診断と治療薬市場の成長と動向Grand View Research, Inc.の最新レポートによると、世界のアレルギー診断・治療薬市場規模は2023年に583億1000万米ドルと推定され、2024年から2030年にかけて年平均成長率(CAGR)8.7%で成長すると予測されている。アレルギー疾患の罹患率の増加は、先進的な治療薬への需要と相まって、今後数年間の市場成長を促進すると予測されている。米国アレルギー喘息免疫学会(AAAAI)が発表した推計によると、アレルギー性鼻炎は世界人口の約10〜30%が罹患しており、世界的にアレルギー治療薬の採用に影響を与えている。 治療成績の向上や疾病管理のための人工知能技術の使用など、技術的に高度な製品の統合が進んでいることは、開業医の意思決定プロセスに役立っている。さらに、鼻炎などのアレルギーを診断するためのmHealthアプリの採用が増加していることも、市場を押し上げると予想される。例えば、MASK-Airアプリはアレルギー性鼻炎に特化している。 モノクローナル抗体は、その高い有効性、長期にわたる忍容性、安全性により、特定のアレルギーの懸念を払拭する新しい治療法の開発に貢献すると予想される。そのため、主要企業は、特にモノクローナル抗体のような選択的な標的を対象とした、標的特異的なメカニズムで設計された新規かつ効果的な生物学的製剤を開発している。さらに、アレルギー疾患に対する非常に重要なモノクローナル抗体の一貫した製品承認は、成長の範囲を拡大すると予想される。 抗免疫グロブリンE(IgE)抗体、サイトカインモジュレーター、DNAワクチン接種などの新しい治療法がアレルギー疾患の治療に用いられている。オマリズマブは組換えヒト化IgG1モノクローナル抗IgE抗体で、アレルギー性の慢性蕁麻疹や喘息の治療に使用される。2021年4月、ジェネンテック(ロシュ・グループ)は、自己注射用プレフィルドシリンジが、慢性特発性蕁麻疹アレルギー性喘息および鼻ポリープを適応症とするゾレア(オマリズマブ)のFDA承認を米国で取得したと発表した。 アレルギー診断薬・治療薬市場は、Merck & Co., Inc.、Thermo Fisher Scientific, Inc.、Abbott、Pfizer, Inc.これらの企業は、能力を高め、製品ポートフォリオを拡大し、能力を向上させるために様々な取り組みを行っている。 アレルギー診断と治療薬市場レポートハイライト - 消耗品製品セグメントは、2022年のアレルギー診断薬・治療薬市場で最大のシェアを占めた。感度、精度、検出速度の向上につながるMeDALLアレルゲンチップを含む製品の登場が市場成長を促進すると予測される - 薬物アレルギー分野は、治療選択肢の増加や患者の薬物アレルギーに対する意識の高まりにより、高成長が期待される。 - 喘息、鼻炎、アレルギー性結膜炎などのアレルギー発症率の増加、世界的なアレルギー検査需要の高まりにより、2022年は試験管内検査が最も高いシェアを占める - エピネフリンが2022年の薬物クラス別セグメントを支配。主要企業による費用対効果の高いエピネフリン自己注射器の導入は、市場成長を大幅に増大させると予想される - 2022年のアレルギー診断薬・治療薬市場は、アレルギー治療薬に関連する高い可能性に対する理解の高まりにより、北米が支配的となった。このため、米国を拠点とする企業は、これらの医薬品の開発にかなりの投資を行うようになった。 - アジア太平洋地域は、特に喘息、慢性咳嗽、食物アレルギーの罹患率が上昇していることから、今後かなりの成長が見込まれる。 目次Table of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Market Definitions 1.3. Information Procurement 1.3.1. Purchased Database 1.3.2. GVR’s Internal Database 1.3.3. Secondary Sources & Third-Party Perspectives 1.3.4. Primary Research 1.3.5. Details of Primary Research 1.4. Information Analysis 1.4.1. Data Analysis Models 1.5. Market Formulation & Data Visualization 1.5.1. Commodity Flow Analysis 1.5.1.1. Approach 1: Commodity flow approach 1.5.1.2. Approach 2: Country-wise market estimation using bottom-up approach 1.6. Data Validation & Publishing 1.7. Global Market: CAGR Calculation 1.8. List of Secondary Sources 1.9. List of Primary Sources Chapter 2. Executive Summary 2.1. Market Snapshot 2.2. Segmental Snapshot 2.3. Competitive Insights Snapshot Chapter 3. Market Variables, Trends, and Scope 3.1. Market Lineage 3.1.1. Parent Market Analysis 3.1.2. Ancillary Market Analysis 3.2. Allergy Diagnostics & Therapeutics Market - Market Dynamics 3.2.1. Market Driver Analysis 3.2.1.1. Rising incidence of allergies 3.2.1.2. Advancements in technology and launch of new products 3.2.1.3. High adoption of immunotherapy drugs 3.2.2. Market Restraint Analysis 3.2.2.1. Low adoption and penetration in developing countries due to the high cost of technology 3.2.2.2. Lack of allergen standardization 3.3. Business Environmental Tools Analysis: Allergy Diagnostics & Therapeutics Market 3.3.1. Porter’s Five Forces Analysis 3.3.2. PESTLE Analysis 3.4. Pipeline Analysis Chapter 4. Allergy Diagnostics & Therapeutics Market: Type Estimates & Trend Analysis 4.1. Allergy Diagnostics & Therapeutics Market, By Type: Key Takeaways 4.2. Allergy Diagnostics & Therapeutics Market: Type Movement & Market Share Analysis, 2023 & 2030 4.3. Diagnostics 4.3.1. Global Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.3.2. Instruments 4.3.2.1. Global Instruments Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.3.3. Consumables 4.3.3.1. Global Consumables Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.3.4. Services 4.3.4.1. Global Services Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4. Therapeutics 4.4.1. Global Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.2. Antihistamines 4.4.2.1. Global Antihistamines Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.3. Decongestants 4.4.3.1. Global Decongestants Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.4. Corticosteroids 4.4.4.1. Global Corticosteroids Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.5. Mast Cell Stabilizers 4.4.5.1. Global Mast Cell Stabilizers Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.6. Leukotriene Inhibitors 4.4.6.1. Global Leukotriene Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.7. Nasal Anti-cholinergic 4.4.7.1. Global Nasal Anti-cholinergic Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.8. Immuno-modulators 4.4.8.1. Global Immuno-modulators Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.9. Epinephrine 4.4.9.1. Global Epinephrine Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.10. Immunotherapy 4.4.10.1. Global Immunotherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million) Chapter 5. Allergy Diagnostics & Therapeutics Market: Allergen Type Estimates & Trend Analysis 5.1. Allergy Diagnostics & Therapeutics Market, By Allergen type: Key Takeaways 5.2. Allergy Diagnostics & Therapeutics Market: Allergen type Movement & Market Share Analysis, 2023 & 2030 5.3. Food 5.3.1. Global Food Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.2. Dairy Products 5.3.2.1. Global Dairy Products Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.3. Poultry Product 5.3.3.1. Global Poultry Products Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.4. Tree Nuts 5.3.4.1. Global Tree Nuts Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.5. Peanuts 5.3.5.1. Global Peanut Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.6. Shellfish 5.3.6.1. Global Shellfish Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.7. Wheat 5.3.7.1. Global Wheat Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.8. Soy 5.3.8.1. Global Soy Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.9. Other Food Allergens 5.3.9.1. Global Food Allergens Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.4. Inhaled 5.4.1. Global Inhaled Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.5. Drug 5.5.1. Global Drug Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.6. Others allergen types 5.6.1. Global Other allergen types Market Estimates And Forecasts, 2018 - 2030 (USD Million) Chapter 6. Allergy Diagnostics Market: Test Type Estimates & Trend Analysis 6.1. Allergy Diagnostics Market, By Test Type: Key Takeaways 6.2. Allergy Diagnostics Market: Test Type Movement & Market Share Analysis, 2023 & 2030 6.3. In Vivo tests 6.3.1. Global In Vivo tests Market Estimates And Forecasts, 2018 - 2030 (USD Million) 6.3.2. Skin Prick Test 6.3.2.1. Global Skin Prick Test Market Estimates And Forecasts, 2018 - 2030 (USD Million) 6.3.3. Intradermal Test 6.3.3.1. Global Intradermal Test Market Estimates And Forecasts, 2018 - 2030 (USD Million) 6.3.4. Patch Test 6.3.4.1. Global Patch Test Market Estimates And Forecasts, 2018 - 2030 (USD Million) 6.4. In Vitro tests 6.4.1. Global In Vitro tests Market Estimates And Forecasts, 2018 - 2030 (USD Million) Chapter 7. Allergy Diagnostics & Therapeutics Market: Regional Estimates & Trend Analysis 7.1. Allergy Diagnostics & Therapeutics Market: Regional Movement Analysis, 2023 & 2030 7.2. North America 7.2.1. North America Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.2.2. U.S. 7.2.2.1. Key Country Dynamics 7.2.2.2. Competitive Scenario 7.2.2.3. Prevalence Insights 7.2.2.4. Regulatory Framework 7.2.2.5. Reimbursement Structure 7.2.2.6. U.S. Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.2.3. Canada 7.2.3.1. Key Country Dynamics 7.2.3.2. Competitive Scenario 7.2.3.3. Prevalence Insights 7.2.3.4. Regulatory Framework 7.2.3.5. Reimbursement Structure 7.2.3.6. Canada Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3. Europe 7.3.1. Europe Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.2. UK 7.3.2.1. Key Country Dynamics 7.3.2.2. Competitive Scenario 7.3.2.3. Prevalence Insights 7.3.2.4. Regulatory Framework 7.3.2.5. Reimbursement Structure 7.3.2.6. UK Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.3. Germany 7.3.3.1. Key Country Dynamics 7.3.3.2. Competitive Scenario 7.3.3.3. Prevalence Insights 7.3.3.4. Regulatory Framework 7.3.3.5. Reimbursement Structure 7.3.3.6. Germany Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.4. France 7.3.4.1. Key Country Dynamics 7.3.4.2. Competitive Scenario 7.3.4.3. Prevalence Insights 7.3.4.4. Regulatory Framework 7.3.4.5. Reimbursement Structure 7.3.4.6. France Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.5. Italy 7.3.5.1. Key Country Dynamics 7.3.5.2. Competitive Scenario 7.3.5.3. Prevalence Insights 7.3.5.4. Regulatory Framework 7.3.5.5. Reimbursement Structure 7.3.5.6. Italy Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.6. Spain 7.3.6.1. Key Country Dynamics 7.3.6.2. Competitive Scenario 7.3.6.3. Prevalence Insights 7.3.6.4. Regulatory Framework 7.3.6.5. Reimbursement Structure 7.3.6.6. Spain Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.7. Denmark 7.3.7.1. Key Country Dynamics 7.3.7.2. Competitive Scenario 7.3.7.3. Prevalence Insights 7.3.7.4. Regulatory Framework 7.3.7.5. Reimbursement Structure 7.3.7.6. Denmark Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.8. Sweden 7.3.8.1. Key Country Dynamics 7.3.8.2. Competitive Scenario 7.3.8.3. Prevalence Insights 7.3.8.4. Regulatory Framework 7.3.8.5. Reimbursement Structure 7.3.8.6. Sweden Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.9. Norway 7.3.9.1. Key Country Dynamics 7.3.9.2. Competitive Scenario 7.3.9.3. Prevalence Insights 7.3.9.4. Regulatory Framework 7.3.9.5. Reimbursement Structure 7.3.9.6. Norway Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4. Asia Pacific 7.4.1. Asia Pacific Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4.2. Japan 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Prevalence Insights 7.4.2.4. Regulatory Framework 7.4.2.5. Reimbursement Structure 7.4.2.6. Japan Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4.3. China 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Prevalence Insights 7.4.3.4. Regulatory Framework 7.4.3.5. Reimbursement Structure 7.4.3.6. China Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4.4. India 7.4.4.1. Key Country Dynamics 7.4.4.2. Competitive Scenario 7.4.4.3. Prevalence Insights 7.4.4.4. Regulatory Framework 7.4.4.5. Reimbursement Structure 7.4.4.6. India Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4.5. Australia 7.4.5.1. Key Country Dynamics 7.4.5.2. Competitive Scenario 7.4.5.3. Prevalence Insights 7.4.5.4. Regulatory Framework 7.4.5.5. Reimbursement Structure 7.4.5.6. Australia Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4.6. Thailand 7.4.6.1. Key Country Dynamics 7.4.6.2. Competitive Scenario 7.4.6.3. Prevalence Insights 7.4.6.4. Regulatory Framework 7.4.6.5. Reimbursement Structure 7.4.6.6. Thailand Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4.7. South Korea 7.4.7.1. Key Country Dynamics 7.4.7.2. Competitive Scenario 7.4.7.3. Prevalence Insights 7.4.7.4. Regulatory Framework 7.4.7.5. Reimbursement Structure 7.4.7.6. South Korea Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.5. Latin America 7.5.1. Latin America Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.5.2. Brazil 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Prevalence Insights 7.5.2.4. Regulatory Framework 7.5.2.5. Reimbursement Structure 7.5.2.6. Brazil Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.5.3. Mexico 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Prevalence Insights 7.5.3.4. Regulatory Framework 7.5.3.5. Reimbursement Structure 7.5.3.6. Mexico Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.5.4. Argentina 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Prevalence Insights 7.5.4.4. Regulatory Framework 7.5.4.5. Reimbursement Structure 7.5.4.6. Argentina Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.6. Middle East & Africa 7.6.1. Middle East & Africa Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.6.2. South Africa 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Prevalence Insights 7.6.2.4. Regulatory Framework 7.6.2.5. Reimbursement Structure 7.6.2.6. South Africa Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.6.3. Saudi Arabia 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Prevalence Insights 7.6.3.4. Regulatory Framework 7.6.3.5. Reimbursement Structure 7.6.3.6. Saudi Arabia Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.6.4. UAE 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Prevalence Insights 7.6.4.4. Regulatory Framework 7.6.4.5. Reimbursement Structure 7.6.4.6. UAE Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.6.5. Kuwait 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Prevalence Insights 7.6.5.4. Regulatory Framework 7.6.5.5. Reimbursement Structure 7.6.5.6. Kuwait Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Company Categorization 8.2. Company Market Share Analysis, 2023 8.3. Strategy Mapping 8.4. Company Profiles/Listing 8.4.1. R-Biopharm AG 8.4.1.1. Overview 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.1.3. Product Benchmarking 8.4.1.4. Strategic Initiatives 8.4.2. EUROIMMUN Medizinische Labordiagnostika AG 8.4.2.1. Overview 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.2.3. Product Benchmarking 8.4.2.4. Strategic Initiatives 8.4.3. DASIT Group SPA 8.4.3.1. Overview 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.3.3. Product Benchmarking 8.4.3.4. Strategic Initiatives 8.4.4. AESKU.GROUP GmbH 8.4.4.1. Overview 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.4.3. Product Benchmarking 8.4.4.4. Strategic Initiatives 8.4.5. bioMérieux 8.4.5.1. Overview 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.5.3. Product Benchmarking 8.4.5.4. Strategic Initiatives 8.4.6. Danaher 8.4.6.1. Overview 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.6.3. Product Benchmarking 8.4.6.4. Strategic Initiatives 8.4.7. Thermo Fisher Scientific, Inc 8.4.7.1. Overview 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.7.3. Product Benchmarking 8.4.7.4. Strategic Initiatives 8.4.8. Stallergenes Greer 8.4.8.1. Overview 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.8.3. Product Benchmarking 8.4.8.4. Strategic Initiatives 8.4.9. Minaris Medical America, Inc. 8.4.9.1. Overview 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.9.3. Product Benchmarking 8.4.9.4. Strategic Initiatives 8.4.10. Siemens Healthcare GmbH 8.4.10.1. Overview 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.10.3. Product Benchmarking 8.4.10.4. Strategic Initiatives 8.4.11. Omega Diagnostics Group PLC 8.4.11.1. Overview 8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.11.3. Product Benchmarking 8.4.11.4. Strategic Initiatives 8.4.12. HYCOR Biomedical 8.4.12.1. Overview 8.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.12.3. Product Benchmarking 8.4.12.4. Strategic Initiatives 8.4.13. Lincoln Diagnostics, Inc. 8.4.13.1. Overview 8.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.13.3. Product Benchmarking 8.4.13.4. Strategic Initiatives 8.4.14. Alcon 8.4.14.1. Overview 8.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.14.3. Product Benchmarking 8.4.14.4. Strategic Initiatives 8.4.15. HOB Biotech Group Corp., Ltd. 8.4.15.1. Overview 8.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.15.3. Product Benchmarking 8.4.15.4. Strategic Initiatives 8.4.16. AbbVie Inc. 8.4.16.1. Overview 8.4.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.16.3. Product Benchmarking 8.4.16.4. Strategic Initiatives 8.4.17. Allergy Therapeutics 8.4.17.1. Overview 8.4.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.17.3. Product Benchmarking 8.4.17.4. Strategic Initiatives 8.4.18. Sanofi 8.4.18.1. Overview 8.4.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.18.3. Product Benchmarking 8.4.18.4. Strategic Initiatives 8.4.19. Pfizer Inc. 8.4.19.1. Overview 8.4.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.19.3. Product Benchmarking 8.4.19.4. Strategic Initiatives 8.4.20. Teva Pharmaceutical Industries Ltd. 8.4.20.1. Overview 8.4.20.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.20.3. Product Benchmarking 8.4.20.4. Strategic Initiatives 8.4.21. Sun Pharmaceutical Industries Ltd. 8.4.21.1. Overview 8.4.21.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.21.3. Product Benchmarking 8.4.21.4. Strategic Initiatives 8.4.22. GSK plc 8.4.22.1. Overview 8.4.22.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.22.3. Product Benchmarking 8.4.22.4. Strategic Initiatives 8.4.23. F. Hoffmann-La Roche Ltd. 8.4.23.1. Overview 8.4.23.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.23.3. Product Benchmarking 8.4.23.4. Strategic Initiatives 8.4.24. Merck & Co., Inc. 8.4.24.1. Overview 8.4.24.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.24.3. Product Benchmarking 8.4.24.4. Strategic Initiatives 8.4.25. Astellas Pharma Inc. 8.4.25.1. Overview 8.4.25.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.25.3. Product Benchmarking 8.4.25.4. Strategic Initiatives
SummaryAllergy Diagnostics And Therapuetics Market Growth & Trends Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Market Definitions 1.3. Information Procurement 1.3.1. Purchased Database 1.3.2. GVR’s Internal Database 1.3.3. Secondary Sources & Third-Party Perspectives 1.3.4. Primary Research 1.3.5. Details of Primary Research 1.4. Information Analysis 1.4.1. Data Analysis Models 1.5. Market Formulation & Data Visualization 1.5.1. Commodity Flow Analysis 1.5.1.1. Approach 1: Commodity flow approach 1.5.1.2. Approach 2: Country-wise market estimation using bottom-up approach 1.6. Data Validation & Publishing 1.7. Global Market: CAGR Calculation 1.8. List of Secondary Sources 1.9. List of Primary Sources Chapter 2. Executive Summary 2.1. Market Snapshot 2.2. Segmental Snapshot 2.3. Competitive Insights Snapshot Chapter 3. Market Variables, Trends, and Scope 3.1. Market Lineage 3.1.1. Parent Market Analysis 3.1.2. Ancillary Market Analysis 3.2. Allergy Diagnostics & Therapeutics Market - Market Dynamics 3.2.1. Market Driver Analysis 3.2.1.1. Rising incidence of allergies 3.2.1.2. Advancements in technology and launch of new products 3.2.1.3. High adoption of immunotherapy drugs 3.2.2. Market Restraint Analysis 3.2.2.1. Low adoption and penetration in developing countries due to the high cost of technology 3.2.2.2. Lack of allergen standardization 3.3. Business Environmental Tools Analysis: Allergy Diagnostics & Therapeutics Market 3.3.1. Porter’s Five Forces Analysis 3.3.2. PESTLE Analysis 3.4. Pipeline Analysis Chapter 4. Allergy Diagnostics & Therapeutics Market: Type Estimates & Trend Analysis 4.1. Allergy Diagnostics & Therapeutics Market, By Type: Key Takeaways 4.2. Allergy Diagnostics & Therapeutics Market: Type Movement & Market Share Analysis, 2023 & 2030 4.3. Diagnostics 4.3.1. Global Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.3.2. Instruments 4.3.2.1. Global Instruments Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.3.3. Consumables 4.3.3.1. Global Consumables Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.3.4. Services 4.3.4.1. Global Services Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4. Therapeutics 4.4.1. Global Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.2. Antihistamines 4.4.2.1. Global Antihistamines Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.3. Decongestants 4.4.3.1. Global Decongestants Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.4. Corticosteroids 4.4.4.1. Global Corticosteroids Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.5. Mast Cell Stabilizers 4.4.5.1. Global Mast Cell Stabilizers Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.6. Leukotriene Inhibitors 4.4.6.1. Global Leukotriene Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.7. Nasal Anti-cholinergic 4.4.7.1. Global Nasal Anti-cholinergic Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.8. Immuno-modulators 4.4.8.1. Global Immuno-modulators Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.9. Epinephrine 4.4.9.1. Global Epinephrine Market Estimates And Forecasts, 2018 - 2030 (USD Million) 4.4.10. Immunotherapy 4.4.10.1. Global Immunotherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million) Chapter 5. Allergy Diagnostics & Therapeutics Market: Allergen Type Estimates & Trend Analysis 5.1. Allergy Diagnostics & Therapeutics Market, By Allergen type: Key Takeaways 5.2. Allergy Diagnostics & Therapeutics Market: Allergen type Movement & Market Share Analysis, 2023 & 2030 5.3. Food 5.3.1. Global Food Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.2. Dairy Products 5.3.2.1. Global Dairy Products Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.3. Poultry Product 5.3.3.1. Global Poultry Products Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.4. Tree Nuts 5.3.4.1. Global Tree Nuts Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.5. Peanuts 5.3.5.1. Global Peanut Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.6. Shellfish 5.3.6.1. Global Shellfish Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.7. Wheat 5.3.7.1. Global Wheat Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.8. Soy 5.3.8.1. Global Soy Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.3.9. Other Food Allergens 5.3.9.1. Global Food Allergens Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.4. Inhaled 5.4.1. Global Inhaled Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.5. Drug 5.5.1. Global Drug Market Estimates And Forecasts, 2018 - 2030 (USD Million) 5.6. Others allergen types 5.6.1. Global Other allergen types Market Estimates And Forecasts, 2018 - 2030 (USD Million) Chapter 6. Allergy Diagnostics Market: Test Type Estimates & Trend Analysis 6.1. Allergy Diagnostics Market, By Test Type: Key Takeaways 6.2. Allergy Diagnostics Market: Test Type Movement & Market Share Analysis, 2023 & 2030 6.3. In Vivo tests 6.3.1. Global In Vivo tests Market Estimates And Forecasts, 2018 - 2030 (USD Million) 6.3.2. Skin Prick Test 6.3.2.1. Global Skin Prick Test Market Estimates And Forecasts, 2018 - 2030 (USD Million) 6.3.3. Intradermal Test 6.3.3.1. Global Intradermal Test Market Estimates And Forecasts, 2018 - 2030 (USD Million) 6.3.4. Patch Test 6.3.4.1. Global Patch Test Market Estimates And Forecasts, 2018 - 2030 (USD Million) 6.4. In Vitro tests 6.4.1. Global In Vitro tests Market Estimates And Forecasts, 2018 - 2030 (USD Million) Chapter 7. Allergy Diagnostics & Therapeutics Market: Regional Estimates & Trend Analysis 7.1. Allergy Diagnostics & Therapeutics Market: Regional Movement Analysis, 2023 & 2030 7.2. North America 7.2.1. North America Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.2.2. U.S. 7.2.2.1. Key Country Dynamics 7.2.2.2. Competitive Scenario 7.2.2.3. Prevalence Insights 7.2.2.4. Regulatory Framework 7.2.2.5. Reimbursement Structure 7.2.2.6. U.S. Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.2.3. Canada 7.2.3.1. Key Country Dynamics 7.2.3.2. Competitive Scenario 7.2.3.3. Prevalence Insights 7.2.3.4. Regulatory Framework 7.2.3.5. Reimbursement Structure 7.2.3.6. Canada Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3. Europe 7.3.1. Europe Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.2. UK 7.3.2.1. Key Country Dynamics 7.3.2.2. Competitive Scenario 7.3.2.3. Prevalence Insights 7.3.2.4. Regulatory Framework 7.3.2.5. Reimbursement Structure 7.3.2.6. UK Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.3. Germany 7.3.3.1. Key Country Dynamics 7.3.3.2. Competitive Scenario 7.3.3.3. Prevalence Insights 7.3.3.4. Regulatory Framework 7.3.3.5. Reimbursement Structure 7.3.3.6. Germany Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.4. France 7.3.4.1. Key Country Dynamics 7.3.4.2. Competitive Scenario 7.3.4.3. Prevalence Insights 7.3.4.4. Regulatory Framework 7.3.4.5. Reimbursement Structure 7.3.4.6. France Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.5. Italy 7.3.5.1. Key Country Dynamics 7.3.5.2. Competitive Scenario 7.3.5.3. Prevalence Insights 7.3.5.4. Regulatory Framework 7.3.5.5. Reimbursement Structure 7.3.5.6. Italy Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.6. Spain 7.3.6.1. Key Country Dynamics 7.3.6.2. Competitive Scenario 7.3.6.3. Prevalence Insights 7.3.6.4. Regulatory Framework 7.3.6.5. Reimbursement Structure 7.3.6.6. Spain Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.7. Denmark 7.3.7.1. Key Country Dynamics 7.3.7.2. Competitive Scenario 7.3.7.3. Prevalence Insights 7.3.7.4. Regulatory Framework 7.3.7.5. Reimbursement Structure 7.3.7.6. Denmark Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.8. Sweden 7.3.8.1. Key Country Dynamics 7.3.8.2. Competitive Scenario 7.3.8.3. Prevalence Insights 7.3.8.4. Regulatory Framework 7.3.8.5. Reimbursement Structure 7.3.8.6. Sweden Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.3.9. Norway 7.3.9.1. Key Country Dynamics 7.3.9.2. Competitive Scenario 7.3.9.3. Prevalence Insights 7.3.9.4. Regulatory Framework 7.3.9.5. Reimbursement Structure 7.3.9.6. Norway Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4. Asia Pacific 7.4.1. Asia Pacific Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4.2. Japan 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Prevalence Insights 7.4.2.4. Regulatory Framework 7.4.2.5. Reimbursement Structure 7.4.2.6. Japan Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4.3. China 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Prevalence Insights 7.4.3.4. Regulatory Framework 7.4.3.5. Reimbursement Structure 7.4.3.6. China Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4.4. India 7.4.4.1. Key Country Dynamics 7.4.4.2. Competitive Scenario 7.4.4.3. Prevalence Insights 7.4.4.4. Regulatory Framework 7.4.4.5. Reimbursement Structure 7.4.4.6. India Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4.5. Australia 7.4.5.1. Key Country Dynamics 7.4.5.2. Competitive Scenario 7.4.5.3. Prevalence Insights 7.4.5.4. Regulatory Framework 7.4.5.5. Reimbursement Structure 7.4.5.6. Australia Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4.6. Thailand 7.4.6.1. Key Country Dynamics 7.4.6.2. Competitive Scenario 7.4.6.3. Prevalence Insights 7.4.6.4. Regulatory Framework 7.4.6.5. Reimbursement Structure 7.4.6.6. Thailand Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.4.7. South Korea 7.4.7.1. Key Country Dynamics 7.4.7.2. Competitive Scenario 7.4.7.3. Prevalence Insights 7.4.7.4. Regulatory Framework 7.4.7.5. Reimbursement Structure 7.4.7.6. South Korea Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.5. Latin America 7.5.1. Latin America Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.5.2. Brazil 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Prevalence Insights 7.5.2.4. Regulatory Framework 7.5.2.5. Reimbursement Structure 7.5.2.6. Brazil Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.5.3. Mexico 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Prevalence Insights 7.5.3.4. Regulatory Framework 7.5.3.5. Reimbursement Structure 7.5.3.6. Mexico Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.5.4. Argentina 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Prevalence Insights 7.5.4.4. Regulatory Framework 7.5.4.5. Reimbursement Structure 7.5.4.6. Argentina Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.6. Middle East & Africa 7.6.1. Middle East & Africa Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.6.2. South Africa 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Prevalence Insights 7.6.2.4. Regulatory Framework 7.6.2.5. Reimbursement Structure 7.6.2.6. South Africa Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.6.3. Saudi Arabia 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Prevalence Insights 7.6.3.4. Regulatory Framework 7.6.3.5. Reimbursement Structure 7.6.3.6. Saudi Arabia Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.6.4. UAE 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Prevalence Insights 7.6.4.4. Regulatory Framework 7.6.4.5. Reimbursement Structure 7.6.4.6. UAE Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) 7.6.5. Kuwait 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Prevalence Insights 7.6.5.4. Regulatory Framework 7.6.5.5. Reimbursement Structure 7.6.5.6. Kuwait Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Company Categorization 8.2. Company Market Share Analysis, 2023 8.3. Strategy Mapping 8.4. Company Profiles/Listing 8.4.1. R-Biopharm AG 8.4.1.1. Overview 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.1.3. Product Benchmarking 8.4.1.4. Strategic Initiatives 8.4.2. EUROIMMUN Medizinische Labordiagnostika AG 8.4.2.1. Overview 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.2.3. Product Benchmarking 8.4.2.4. Strategic Initiatives 8.4.3. DASIT Group SPA 8.4.3.1. Overview 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.3.3. Product Benchmarking 8.4.3.4. Strategic Initiatives 8.4.4. AESKU.GROUP GmbH 8.4.4.1. Overview 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.4.3. Product Benchmarking 8.4.4.4. Strategic Initiatives 8.4.5. bioMérieux 8.4.5.1. Overview 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.5.3. Product Benchmarking 8.4.5.4. Strategic Initiatives 8.4.6. Danaher 8.4.6.1. Overview 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.6.3. Product Benchmarking 8.4.6.4. Strategic Initiatives 8.4.7. Thermo Fisher Scientific, Inc 8.4.7.1. Overview 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.7.3. Product Benchmarking 8.4.7.4. Strategic Initiatives 8.4.8. Stallergenes Greer 8.4.8.1. Overview 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.8.3. Product Benchmarking 8.4.8.4. Strategic Initiatives 8.4.9. Minaris Medical America, Inc. 8.4.9.1. Overview 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.9.3. Product Benchmarking 8.4.9.4. Strategic Initiatives 8.4.10. Siemens Healthcare GmbH 8.4.10.1. Overview 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.10.3. Product Benchmarking 8.4.10.4. Strategic Initiatives 8.4.11. Omega Diagnostics Group PLC 8.4.11.1. Overview 8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.11.3. Product Benchmarking 8.4.11.4. Strategic Initiatives 8.4.12. HYCOR Biomedical 8.4.12.1. Overview 8.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.12.3. Product Benchmarking 8.4.12.4. Strategic Initiatives 8.4.13. Lincoln Diagnostics, Inc. 8.4.13.1. Overview 8.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.13.3. Product Benchmarking 8.4.13.4. Strategic Initiatives 8.4.14. Alcon 8.4.14.1. Overview 8.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.14.3. Product Benchmarking 8.4.14.4. Strategic Initiatives 8.4.15. HOB Biotech Group Corp., Ltd. 8.4.15.1. Overview 8.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.15.3. Product Benchmarking 8.4.15.4. Strategic Initiatives 8.4.16. AbbVie Inc. 8.4.16.1. Overview 8.4.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.16.3. Product Benchmarking 8.4.16.4. Strategic Initiatives 8.4.17. Allergy Therapeutics 8.4.17.1. Overview 8.4.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.17.3. Product Benchmarking 8.4.17.4. Strategic Initiatives 8.4.18. Sanofi 8.4.18.1. Overview 8.4.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.18.3. Product Benchmarking 8.4.18.4. Strategic Initiatives 8.4.19. Pfizer Inc. 8.4.19.1. Overview 8.4.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.19.3. Product Benchmarking 8.4.19.4. Strategic Initiatives 8.4.20. Teva Pharmaceutical Industries Ltd. 8.4.20.1. Overview 8.4.20.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.20.3. Product Benchmarking 8.4.20.4. Strategic Initiatives 8.4.21. Sun Pharmaceutical Industries Ltd. 8.4.21.1. Overview 8.4.21.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.21.3. Product Benchmarking 8.4.21.4. Strategic Initiatives 8.4.22. GSK plc 8.4.22.1. Overview 8.4.22.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.22.3. Product Benchmarking 8.4.22.4. Strategic Initiatives 8.4.23. F. Hoffmann-La Roche Ltd. 8.4.23.1. Overview 8.4.23.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.23.3. Product Benchmarking 8.4.23.4. Strategic Initiatives 8.4.24. Merck & Co., Inc. 8.4.24.1. Overview 8.4.24.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.24.3. Product Benchmarking 8.4.24.4. Strategic Initiatives 8.4.25. Astellas Pharma Inc. 8.4.25.1. Overview 8.4.25.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.25.3. Product Benchmarking 8.4.25.4. Strategic Initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(アレルギー用薬)の最新刊レポートGrand View Research 社の最新刊レポート
本レポートと同じKEY WORD(diagnostics)の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/09 10:26 149.25 円 164.26 円 198.27 円 |